Merck speeds up drug-submission plans for Hep C, lung cancer -WSJ
January 12, 2015 at 01:50 AM EST
Jan 12 (Reuters) - Merck & Co has put on fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval, in an attempt to close the gap with competitors in two lucrative segments, the Wall Street Journal reported.
